** Shares of drug developer CervoMed CRVO.O rise 4.4% to $6.44
** Brokerage Jones Research upgrades CRVO to "buy" rating from "hold", keeps PT of $15
** Upgrade follows CRVO's announcement of positive results from study of its drug, neflamapimod, in patients with dementia with Lewy bodies $(DLB)$ on Monday
** Data from study is boosting investor confidence, and we are seeing a more riskon approach heading into the next steps for netlamapimod in DLB patients - Jones Research
** DLB is a form of dementia caused by the accumulation of protein deposits called Lewy bodies in the brain's nerve cells
** Up to Wednesday's close, stock up 176.7% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。